This category deals with imaging peripheral and central inflammatory reactions in different pathologies, targeting cellular and tissue markers of inflammation. This category also covers the dynamic non-invasive visualization of the immune response, using innovative imaging technologies, across multiple diseases and following therapeutic intervention, for purposes of tracking immune cells and assessing their interactions with the host and microenvironment. We encourage submissions where the immune system is the primary focus, rather than the disease itself, which might be a better-fit for other disease-specific categories (e.g. oncology track).
Probe & Targets
The design, chemical synthesis and characterization of imaging probes or reporter genes and their targets prior to in vivo applications. Research targeting new biological mechanisms where imaging is used as a tool to gain mechanistic insights into disease are included. All imaging modalities covered.
Preclinical Imaging
All applications where new imaging tools and probes are evaluated in preclinical models belong to this category. It also includes the preclinical testing of previously developed imaging probes for new applications/uses.
Translational and Human Studies
Research on humans or (non-human) studies with demonstrated potential for clinical impact or immediate translation should be submitted to this category. It includes prospective and retrospective studies as well as studies on new pharmaceuticals at phase I-IV where imaging plays a significant role in the study. Studies on Omics and its combination with imaging are also welcome.
Image-guided Therapy and Theranostics
Research spanning theranostic repurposing of existing molecular imaging probes to combine therapeutic and diagnostic capabilities in a single platform, and/or exploration of novel ways to integrate molecular imaging with conventional therapies to guide treatment monitoring. Preclinical testing of theranostic agents/strategies towards real-time monitoring and treatment of inflammatory and immune-driven diseases are covered, including their clinical evaluation in human subjects.